Invasive Breast Cancer Articles & Analysis: Older
23 news found
The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. ...
The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. ...
Women are increasingly aware of the cancer risk associated with breast density. QVCAD Invenia ABUS combination provides a solution that has the potential to be the preferred screening method for women with dense breast parenchyma. ...
This may allow GLSI-100 to protect breast cancer survivors over longer periods of time against recurring metastatic breast cancer. ...
The trial, NCT05232916, is currently registered on clinicaltrials.gov and can be seen here. About Breast Cancer and HER2/neu Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 282,000 new breast cancer patients and 3.8 ...
The GP2 Phase III clinical trial poster was presented in person at the 2021 annual San Antonio Breast Cancer Symposium (SABCS). The Company was a SABCS sponsor and held a clinical trial planning meeting with investigators at the conference. ...
Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced the publication of SweDCIS randomized clinical trial data in the Special Issue: Updates on Breast Cancer edition of Cancers. ...
Daugherty is expanding his role with a very significant commitment to serve as medical monitor of our upcoming and future clinical trials as we seek to expand GP2’s potential to all HER2 positive breast cancer patients and to explore HER2 low breast cancer and other HER2 expressing cancers. ...
The study, led by the independent SWOG Cancer Research Network and sponsored by the National Cancer Institute (NCI), successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score results of 0 to 25. ...
This is an important inflection point for the company as we work towards establishing a regulatory path to make the ProSense System available in other major markets, such as the United States, China, and Japan as a minimally invasive treatment to early-stage breast cancer patients. I look forward to supporting existing and new employees so that ...
The National Comprehensive Cancer Network (NCCN)viii recently updated its guidelines for breast cancer and recognised the Oncotype DX Breast Recurrence Score test as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with one to three ...
ESR1 mutations are found in primary breast cancers prior to therapy initiation and are associated to worse relapse-free and overall survival. ...
Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis’ Liquid Biopsy Platform in Early Stage Breast Cancer and the Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients Tethis S.p.A announced the publication of a pilot study in early ...
“The discussion was both timely and enlightening, and it is clear that some of the leading players in the space are finally beginning to refocus resources on early cancer detection as perhaps the only viable long-term and cost-effective solution to curable approaches in ...
Published studies from multicenter prospective clinical trials suggest that the non-invasive, blood-based IsoPSA assay has significant superior diagnostic accuracy when compared to traditional prostate-specific antigen (PSA) tests in detecting high-grade prostate cancer. ...
” A Disease With a Wide and Terrible Reach Over 268,000 women in the US will be diagnosed with breast cancer in 2019. Approximately 1 in 8 women in the US will develop invasive breast cancer at some point during their lifetime. 62,000 will develop non-invasive (in situ) ...
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online publication of results from a multicenter validation study of IsoPSA™, a novel structure-based prostate cancer assay, in Journal of Urology. The study validated the findings from a preliminary ...
Previously reported data include: At the December 2018 San Antonio Breast Cancer Symposium, Seno’s Medical Director, Dr. Gisela Menezes, presented how the company’s OA/US may play a role in noninvasively offering breast cancer prognostic information at the molecular level. This prospective 5-center study was ...
(Seno Medical), the leader in new technology for breast cancer diagnosis using opto-acoustic (OA/US) imaging to differentiate benign from malignant masses, reported results of a study demonstrating that morphologic and functional OA/US features provide a non-invasive approach to helping distinguish breast cancer ...